UOC
ABBV icon

UBS O'Connor’s AbbVie ABBV Stock Holding History

UBS O'Connor’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,297
Closed -$2.47M – 276
2025
Q2 		$2.47M Buy
13,297
+12,324
+1,267% +$2.29M 0.07% 138
2025
Q1 		$204K Sell
973
-6,515
-87% -$1.27M ﹤0.01% 251
2024
Q4 		$1.33M Buy
7,488
+6,342
+553% +$1.17M 0.03% 208
2024
Q3 		$226K Sell
1,146
-12,049
-91% -$2.25M 0.01% 382
2024
Q2 		$2.26M Buy
13,195
+12,057
+1,059% +$2M 0.06% 175
2024
Q1 		$207K Sell
1,138
-13,583
-92% -$2.34M 0.01% 399
2023
Q4 		$2.28M Sell
14,721
-3,179
-18% -$463K 0.07% 155
2023
Q3 		$2.67M Sell
17,900
-23,700
-57% -$3.48M 0.05% 191
2023
Q2 		$5.6M Buy
41,600
+25,818
+164% +$3.79M 0.12% 101
2023
Q1 		$2.52M Sell
15,782
-1,320
-8% -$202K 0.06% 233
2022
Q4 		$2.76M Buy
17,102
+6,700
+64% +$1.03M 0.05% 334
2022
Q3 		$1.4M Buy
+10,402
New +$1.49M 0.02% 704
2015
Q3 		– Sell
-7,596
Closed -$510K – 512
2015
Q2 		$510K Buy
+7,596
New +$496K ﹤0.01% 696

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS O'Connor's ABBV Position: Q3 2025 in Review

UBS O'Connor sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 13,297 shares — an estimated $2.47M sold.

UBS O'Connor first reported a position in ABBV in Q2 2015 and held it in 13 quarters. The position peaked at $5.6M in Q2 2023. 3,915 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • UBS O'Connor reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 13,297 AbbVie shares in Q3 2025, an estimated $2.47M.
  • UBS O'Connor first reported a position in AbbVie in Q2 2015 and held it in 13 quarters.
  • UBS O'Connor's AbbVie position peaked at $5.6M in Q2 2023.
  • 3,915 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.